References
- Rosário C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: macrophage activation syndrome, still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med [Internet]. 2013 Aug 22 [cited 2020 July 28];11(1):185. Available from: /pmc/articles/PMC3751883/?report=abstract
- Gómez-Pastora J, Weigand M, Kim J, et al. Hyperferritinemia in critically ill COVID-19 patients – is ferritin the product of inflammation or a pathogenic mediator? [Internet]. Clin Chim Acta. 2020 [cited 2020 July 28];509:249–251. Elsevier B.V. Available from:. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306200/
- McGonagle D, Sharif K, O’Regan A, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease [Internet]. Autoimmun Rev. 2020 [cited 2020 July 28];19:102537. Elsevier B.V. Available from:. https://pubmed.ncbi.nlm.nih.gov/32251717/
- Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. UroToday Int J [Internet]. 2009 [cited 2020 Sep 16];2(2):806. Available from: /pmc/articles/PMC2034723/?report=abstract
- Long H, Nie L, Xiang X, et al. D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. Biomed Res Int [Internet]. 2020 [cited 2020 July 29];2020:1–10. Available from: /pmc/articles/PMC7301188/?report=abstract
- Soraya GV, Ulhaq ZS. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis. Med Clin (Barc) [Internet] 2020 [cited 2020 July 29];155:143–151. Available from: /pmc/articles/PMC7274591/?report=abstract
- Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol [Internet]. 2020 July 10 [cited 2020 July 29];7:e671–e678. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32659214
- Ruan Q, Yang K, Wang W, et al. Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China (Intensive Care Medicine, (2020), 46, 5, (846-848), https://doi.org/10.1007/s00134-020-05991-x) [Internet]. Intensive Care Med. 2020 [cited 2020 Sept 4];46:1294–1297. Springer.
- Huang I, Pranata R, Lim MA, et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis [Internet]. 2020 Jan 1 [cited 2020 Sept 4];14:175346662093717. Available from: https://covid19.elsevierpure.com/it/publications/c-reactive-protein-procalcitonin-d-dimer-and-ferritin-in-severe-c
- Recalcati S, Invernizzi P, Arosio P, et al. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun [Internet]. 2008 Feb [cited 2020 July 28];30(1–2):84–89. Available from: https://ucdavis.pure.elsevier.com/en/publications/new-functions-for-an-iron-storage-protein-the-role-of-ferritin-in
- Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning [Internet]. Autoimmun Rev. 2020 [cited 2020 July 28];19:102538. Elsevier B.V. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131471/
- Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China [Internet]. Clin Immunol. 2020 [cited 2020 July 28];214:108393. Academic Press Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/32222466/
- Ruscitti P, Berardicurti O, Iagnocco A, et al. Cytokine storm syndrome in severe COVID-19 [Internet]. Autoimmun Rev. 2020 [cited 2020 July 28];19:102562. Elsevier B.V. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252135/
- Colafrancesco S, Priori R, Alessandri C, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res [Internet]. 2014 Dec 9 [cited 2020 July 29];60(2–3):177–183. Available from: https://pubmed.ncbi.nlm.nih.gov/25388964/
- Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect [Internet]. 2020 June 1 [cited 2020 July 28];80(6):656–665. Available from: /pmc/articles/PMC7151416/?report=abstract
- Madoiwa S. Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC [Internet]. J Intensive Care. 2015 [cited 2020 July 28];3:8. BioMed Central Ltd. Available from: /pmc/articles/PMC4940964/?report=abstract
- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med [Internet]. 2020 July 17 [cited 2020 July 29];NEJMoa2021436. Available from: http://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa2021436
- Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol [Internet]. 2020 June 1 [cited 2020 Sep 16];127:104380. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194791/
- Khiali S, Khani E, Entezari-Maleki T, et al. Review of tocilizumab in COVID-19 acute respiratory distress syndrome [Internet]. J Clin Pharmacol. 2020 [cited 2020 Sept 16];60:1131–1146. Blackwell Publishing Inc. Available from: https://pubmed.ncbi.nlm.nih.gov/32557541/